LifeStance Health Group (NASDAQ:LFST) Director Sells $558,206.30 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 79,630 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $7.01, for a total transaction of $558,206.30. Following the completion of the transaction, the director owned 1,382,175 shares in the company, valued at $9,689,046.75. This represents a 5.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $86,597.00.

LifeStance Health Group Stock Down 0.6%

LFST traded down $0.04 during trading on Tuesday, hitting $6.88. The company had a trading volume of 2,536,438 shares, compared to its average volume of 1,978,562. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The company has a market cap of $2.68 billion, a PE ratio of -229.33 and a beta of 1.13. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $8.30. The business has a 50-day moving average of $5.90 and a 200-day moving average of $5.34.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The firm’s revenue was up 16.3% on a year-over-year basis. As a group, analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Institutional Trading of LifeStance Health Group

A number of hedge funds have recently modified their holdings of LFST. AustralianSuper Pty Ltd acquired a new stake in shares of LifeStance Health Group in the third quarter worth $17,056,000. Vanguard Group Inc. boosted its position in LifeStance Health Group by 19.5% during the 3rd quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock worth $80,374,000 after acquiring an additional 2,383,728 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after acquiring an additional 1,839,465 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of LifeStance Health Group by 27.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares during the period. Finally, Integral Health Asset Management LLC acquired a new stake in shares of LifeStance Health Group during the third quarter worth approximately $8,250,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on LFST. Barclays assumed coverage on LifeStance Health Group in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target for the company. Wall Street Zen lowered shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday. Finally, BTIG Research boosted their target price on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.